drugset / Trial / NCT00337610

Sitagliptin Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus

NCT00337610

Phase 3 Completed 190 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

A clinical study to determine the safety and efficacy of sitagliptin in patients with Type 2 Diabetes Mellitus who have inadequate glycemic (blood sugar) control on metformin therapy.

Timeline

Start
2006-06
Primary completion
2007-05
Completion
2007-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Sitagliptin Small molecule 100 mg Oral
Background Metformin Small molecule 1500 mg Oral